Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.35 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969531 | 1.00 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL5112759 | 0.92 | MAPT (0.40) | CSNK2A1EGFRMAPTSYKTP53 | |
| SCHEMBL5123062 | 0.91 | MAPT (0.40) | CSNK2A1EGFRMAPTSYKTP53 | |
| SCHEMBL4968835 | 0.90 | SYK (0.40) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL4966654 | 0.90 | SYK (0.40) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL5122474 | 0.81 | MAPT (0.40) | EGFRMAPTSYKTP53ABCG2 | |
| SCHEMBL5108932 | 0.79 | EGFR (0.35) | EGFRERBB2 | |
| SCHEMBL27067 | 0.78 | EGFR (0.43) | CSNK2A1CSNK2A2CSNK2BEGFRERBB2 | |
| SCHEMBL4865132 | 0.73 | AURKA (0.52) | EGFRERBB2ERBB4 | |
| SCHEMBL4865572 | 0.73 | EGFR (0.42) | CSNK2A1EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| EP-1957468-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | T.K. Signal Ltd. (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007029251-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE | T.K. SIGNAL LTD. (IL) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | CSNK2A1 1777/4885CSNK2A2 2077/4885CSNK2B 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.